Show simple item record

dc.contributor.authorMorón, Rocío
dc.contributor.authorGálvez Peralta, Julio Juan 
dc.contributor.authorColmenero, Manuel
dc.contributor.authorAnderson, Per Olof
dc.contributor.authorCabeza, José
dc.contributor.authorRodríguez Cabezaas, María Elena
dc.identifier.citationMoron, R., Galvez, J., Colmenero, M., Anderson, P., Cabeza, J., & Rodriguez-Cabezas, M. E. (2019). The Importance of the Microbiome in Critically Ill Patients: Role of Nutrition. Nutrients, 11(12), 3002.es_ES
dc.description.abstractCritically ill patients have an alteration in the microbiome in which it becomes a disease-promoting pathobiome. It is characterized by lower bacterial diversity, loss of commensal phyla, like Firmicutes and Bacteroidetes, and a domination of pathogens belonging to the Proteobacteria phylum. Although these alterations are multicausal, many of the treatments administered to these patients, like antibiotics, play a significant role. Critically ill patients also have a hyperpermeable gut barrier and dysregulation of the inflammatory response that favor the development of the pathobiome, translocation of pathogens, and facilitate the emergence of sepsis. In order to restore the homeostasis of the microbiome, several nutritional strategies have been evaluated with the aim to improve the management of critically ill patients. Importantly, enteral nutrition has proven to be more efficient in promoting the homeostasis of the gut microbiome compared to parenteral nutrition. Several nutritional therapies, including prebiotics, probiotics, synbiotics, and fecal microbiota transplantation, are currently being used, showing variable results, possibly due to the unevenness of clinical trial conditions and the fact that the beneficial effects of probiotics are specific to particular species or even strains. Thus, it is of great importance to better understand the mechanisms by which nutrition and supplement therapies can heal the microbiome in critically ill patients in order to finally implement them in clinical practice with optimal safety and efficacy.es_ES
dc.description.sponsorshipThis work was supported by Junta de Andalucía (Spain) (research grants CTS 164 and PI-0206-2016) and cofinanced by the Fondo Europeo de Desarollo Regional (FEDER) from the European Union. RM has a Río Hortega contract (CM17/00237) and PA has a Nicolás Monardes contract (C-0013-2018).es_ES
dc.rightsAtribución 3.0 España*
dc.subjectCritically ill patientes_ES
dc.subjectNutrition es_ES
dc.subjectFecal microbiota transplantationes_ES
dc.titleThe Importance of the Microbiome in Critically Ill Patients: Role of Nutritiones_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España